Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors.
The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects.
This research study involves the study drugs Afatinib and Pemigatinib.